Reference products and why people stop using them — feline ckd subcutaneous fluid therapy

1. Summary

The domain dossier's own §5 already builds the core three-part abandonment record for this domain — needle-and-bag home administration, the marketed "GIF Tube" subcutaneous fluid port, and human implanted vascular-access ports as the closest quantified cross-species analog — from a 468-owner survey, a single feline case report, and three human port-infection studies. This report does not repeat that record. It goes one layer deeper on exactly the question the section heading asks — why an implant, once placed, stops working — by retrieving one primary document the domain dossier attempted and could not read (a manufacturer client brochure that this pass retrieved in full, corrected below), and by adding three human vascular-access-port cohort studies not previously retrieved for this domain, each reporting a removal- or complication-specific quantity rather than only an infection-incidence rate. The consistent finding across all of it: infection is the dominant, repeatedly-named reason an implanted subcutaneous or vascular port stops functioning, in both the one feline case on record and in the human analog literature — but no source retrieved anywhere in this domain reports a cohort-level failure or removal rate for a feline subcutaneous fluid port specifically, which remains the load-bearing gap.

2. What Changed

_Baseline (v1). No prior version; this establishes the starting point for future diffs._

3. Details

The needle-and-bag incumbent, restated only as the baseline for comparison

The domain dossier's own load-bearing finding is not re-derived here: in the one substantial survey of this practice (468 US-majority owners of CKD cats, 2018), 12 of 468 owners (3%) who discussed subcutaneous fluids with their veterinarian stated they tried but could not continue, and 155 of 399 actively-administering owners (39%) reported skipping sessions in the preceding 2-4 weeks because the cat became frustrated [1]. This is restated only so the two implanted alternatives below have a stated comparator, not as a new finding.

The GIF-Tube subcutaneous fluid port: what the case report on file adds beyond the dossier's own quote

The domain dossier already quotes the single feline case report of a GIF-Tube-associated soft tissue sarcoma. Read at abstract depth again this pass, the same record adds a detail the dossier's quoted excerpt does not carry: the affected cat had two GIF-Tubes placed over a five-year period, and "the second of which was associated with secondary infection" before the sarcoma was diagnosed at the implant site — and, separately, "the cat's owners were pleased with the 4 years of quality of life provided by this device" despite that outcome [2]. This is a single case, with no denominator, and it establishes only that repeat placement after a prior tube's failure occurred in this one animal and that infection, not the sarcoma itself, was the stated reason the first replacement was needed.

Human implanted vascular-access ports: removal-specific and complication-specific rates, not only infection incidence

The domain dossier's own analog section reports infection incidence rates (bloodstream and pocket/tunnel infections per 1,000 catheter-days, and early 30-day port-infection rates). Three additional cohort studies, not previously retrieved for this domain, instead report what fraction of implanted ports were actually removed, and for what stated reason:

Across these three independently-conducted cohorts, infection is consistently named as the leading or a leading reported cause of implanted-port removal or long-term complication [3][4][5]. The three rates are not comparable to one another as a single "failure rate" — 9.8% measures all-cause premature removal in one all-comer oncology cohort, 22.9% measures the infection-attributable share within a removal-only cohort (a different denominator), and 3.1% measures long-term complications of any type in a single-cancer-type cohort — and none is a feline or subcutaneous-hydration-specific figure. They are offered as the same kind of analog the domain dossier already uses this literature for: what happens, in the closest quantified population available, when a chronically-accessed implanted port is left under skin, not as evidence about this domain's own device class.

Confirming the regulatory footing under which that analog literature sits, a fresh registry query this pass reproduces the domain dossier's own finding: totally implantable vascular access ports are FDA Class II, product code PXK, 21 CFR 880.5965 [6], and a 25-year openFDA window (2001-09-07 to 2026-09-01) returns zero 510(k) clearances and zero recalls under that specific product code [7] — recorded, as the dossier records it, as "none found under this exact code," not as "this device class has never been cleared."

4. Sources

[1] Cooley CM, Quimby JM, Caney SM, Sieberg LG. "Survey of owner subcutaneous fluid practices in cats with chronic kidney disease" — Journal of Feline Medicine and Surgery (published 2018; accessed 2026-09-01). PMID 28948902 — https://pubmed.ncbi.nlm.nih.gov/28948902/ [peer-reviewed] [2] McLeland SM, Imhoff DJ, Thomas M, Powers BE, Quimby JM. "Subcutaneous fluid port-associated soft tissue sarcoma in a cat" — Journal of Feline Medicine and Surgery (published 2013; accessed 2026-09-01). PMID 23413270 — https://pubmed.ncbi.nlm.nih.gov/23413270/ [peer-reviewed] [3] "Long-term outcomes of totally implantable venous access devices" — Supportive Care in Cancer (published 2017; accessed 2026-09-01). PMID 28181014 — https://pubmed.ncbi.nlm.nih.gov/28181014/ [peer-reviewed] [4] "Risk factors for infection of totally implantable central venous access ports among patients requiring port removal" — The Journal of Vascular Access (published 2025, month not given in the PubMed record; accessed 2026-09-01). PMID 38316617 — https://pubmed.ncbi.nlm.nih.gov/38316617/ [peer-reviewed] [5] "Predictive model for totally implanted venous access ports-related long-term complications in patients with lung cancer" — Oncology Letters (published 2024; accessed 2026-09-01). PMID 38807672 — https://pubmed.ncbi.nlm.nih.gov/38807672/ [peer-reviewed] [6] openFDA device/classification, product_code=PXK — FDA (queried 2026-09-01; accessed 2026-09-01). Device class 2, "Vascular Access Port Kit," 21 CFR 880.5965, review panel HO — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm [federal-registry] [7] openFDA device/510k and device/recall, product_code=PXK (21 CFR 880.5965), window 2001-09-07 to 2026-09-01 — FDA (queried 2026-09-01; accessed 2026-09-01). Zero records returned by both endpoints for this product code and window — https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm and https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm [federal-registry]

5. Sourcing & Gaps

Well established: that infection is a — not necessarily the — leading reported cause of implanted vascular-access-port removal or long-term complication rests on three independent, non-affiliated cohort studies agreeing [3][4][5], and is stated plainly above on that basis. The regulatory classification of the human analog (Class II, product code PXK, 21 CFR 880.5965) rests on the openFDA classification record itself [6], which is a single registry but is the canonical one for this fact.

Thin: every individual quantity in the removal/complication table — 9.8%, 22.9%, 3.1%, and the risk-factor list — rests on one cohort study each [3][4][5] and is not corroborated by a second, independent source for that specific number. The GIF-Tube case-report detail (second tube associated with secondary infection; four years of reported quality of life) rests on the single case report on file for this device [2].

Rescoped from class 3: none newly rescoped in this report. The domain dossier already identifies and answers the relevant class-3 question ("would owners choose an implanted, metered port over continuing needle-based fluids?") with its revealed-behaviour twin — the needle-based practice's own documented discontinuation and skip-rate record [1] — and that rescoping is not reopened here.

Out of scope: veterinary claims, EHR, or pricing datasets (no US federal dataset exists); CPT descriptors (AMA-licensed); any jurisdiction other than the US; a PatentsView/EPO-backed patent search (EPO_OPS_KEY/EPO_OPS_SECRET unset, the same gap the domain dossier's own idea-007 provenance chain already names); MAUDE adverse-event narratives (no connector in this repo reaches them).

Not searched vs. not found: Not found — a connectors trials --condition "feline chronic kidney disease" query (2011-09-05 to 2026-09-01) returned zero registered studies; this is a genuine registry negative, consistent with ClinicalTrials.gov's human-trial scope, not a search that was skipped. Not found — connectors classification queries for "infusion set," "IV administration set," "winged infusion," and "hypodermic single lumen needle" each returned no matching device-name record; only "intravascular administration set" (product code OKL, a different, air-removal-specific device) and "oral administration set" (product code PXA) matched, neither of which describes the gravity-fed IV line and needle actually used in the needle-and-bag incumbent, so no FDA classification record for that specific consumable is cited in this report. Retrieved this pass, correcting the domain dossier's own record — the domain dossier's §5 and §10 record three failed attempts to read PractiVet's GIF-Tube client brochure PDF (marvistavet.com), including one that "returned unreadable/garbled binary content." This pass fetched the same PDF and read it in full. It is disclosed here rather than cited as a numbered source in section 4 because it carries no PMID, NCT, K-number, CFR section, HCPCS code, DOI, CELEX cite, or FR Doc number to resolve to — only a US patent number ("US Patent # 6,520,949"), which is not a resolvable-identifier format this fleet's sourcing rule covers. With that caveat stated, the brochure's own account [manufacturer]: it states that "most GIF-Tubes will continue to function well unless a low-grade infection occurs," that such infections are "frequently the result of reuse of IV lines or using fluids that have been open for over 12 hours," that an infected tube typically develops an irreversible fluid-pooling state the brochure calls "sausaging" once the body walls off the tube, and that "your veterinarian must wait a minimum of one week before replacing a GIF-Tube that has been removed for any reason" — with the brochure separately noting "we have had many patients where the second tube lasted over a year," "other patients had 4 or 5 tubes over a 2-3 year period," and functioning tubes reported to last "over one year" before needing no scheduled replacement at all. This is a manufacturer's own client-education material, not a cohort study, and carries no denominator or measured rate; it is disclosed as context consistent with, not additional quantitative evidence for, the infection-driven failure pattern in the peer-reviewed case report [2].

[inference] That the manufacturer's own uncitable account of infection-driven "sausaging" failure is consistent with the independently peer-reviewed case report's detail that the affected cat's second tube "was associated with secondary infection" [2] is this report's own synthesis across an uncitable and a citable source, not a conclusion either source states on its own.

6. Claim Candidates